Humacyte (HUMA) Total Non-Current Liabilities (2020 - 2026)
Humacyte (HUMA) posted quarterly Total Non-Current Liabilities of $97.3 million for Q1 2026, down 22.54% year-over-year from $125.6 million in Q1 2025, and down 12.91% quarter-over-quarter from $111.7 million in Q4 2025.
Humacyte (HUMA) Total Non-Current Liabilities (2020 - 2026) Analysis & Trends
Humacyte (HUMA) has reported Total Non-Current Liabilities for 7 consecutive years, with $97.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 22.54% year-over-year to $97.3 million; the TTM figure through Mar 2026 stood at $97.3 million (down 22.54% YoY), while the FY2025 annual figure was $111.7 million, down 40.64% from the prior year.
- Total Non-Current Liabilities eased to $97.3 million in Q1 2026 per HUMA's latest filing, from $111.7 million in the prior quarter.
- Across five years, Total Non-Current Liabilities topped out at $188.1 million in Q4 2024 and bottomed at $59.0 million in Q1 2023.
- Historically, Total Non-Current Liabilities has averaged $112.2 million across 5 years, with a median of $109.9 million in 2023.
- On a YoY basis, Total Non-Current Liabilities climbed as much as 6975.65% in 2022 and fell as far as 72.44% in 2022.
- Humacyte's Total Non-Current Liabilities stood at $86.7 million in 2022, then grew by 29.29% to $112.0 million in 2023, then jumped by 67.91% to $188.1 million in 2024, then slumped by 40.64% to $111.7 million in 2025, then dropped by 12.91% to $97.3 million in 2026.
- Business Quant data shows HUMA's Total Non-Current Liabilities at $97.3 million in Q1 2026, $111.7 million in Q4 2025, and $93.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.20 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.17 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.32 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 724.15 Mn |
| 10 | Humacyte | 158.12 Mn | 158.12 Mn | -825,000.00 | 91.18 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 91.18 Mn |
| Mar 31, 2026 | 97.26 Mn |
| Dec 31, 2025 | 111.67 Mn |
| Sep 30, 2025 | 93.03 Mn |
| Jun 30, 2025 | 133.76 Mn |
| Mar 31, 2025 | 125.56 Mn |
| Dec 31, 2024 | 188.13 Mn |
| Sep 30, 2024 | 101.92 Mn |
| Jun 30, 2024 | 165.30 Mn |
| Mar 31, 2024 | 134.48 Mn |
| Dec 31, 2023 | 112.04 Mn |
| Sep 30, 2023 | 109.86 Mn |
| Jun 30, 2023 | 106.10 Mn |
| Mar 31, 2023 | 59.01 Mn |
| Dec 31, 2022 | 86.66 Mn |
| Sep 30, 2022 | 62.54 Mn |
| Jun 30, 2022 | 60.06 Mn |
| Mar 31, 2022 | 160.16 Mn |
| Dec 31, 2021 | 60.70 Mn |
| Sep 30, 2021 | 226.95 Mn |